Tag: GlobeNewswire

PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its participation in the 2026 Congress of Neurological Surgeons (CNS) Annual Meeting, taking place October 31-November 4 in Washington, D.C. At this year’s meeting, Integra will showcase its comprehensive neurosurgery portfolio through interactive educational experiences, hands-on training and technologies that support neurosurgeons across the continuum of care.

Conference attendees are invited to visit Integra at Booth 341 and participate in the CNS Skills Showdown, an interactive, educational experience that allows surgeons to test and refine procedural skills while learning about innovative neurosurgical technologies.

In addition, Integra will host a mobile hands-on laboratory on-site on Tuesday, November 3, providing attendees with practical product training opportunities across key areas of neurosurgical care, including:

• Aurora® Surgiscope® System
• DuraGen®Dural Graft Matrices, Durepair® Dura Regeneration Matrix and dural repair solutions
• CUSA® Clarity Ultrasonic Surgical Aspirator System
• Neurocritical care technologies and intracranial pressure (ICP) monitoring solutions

“As a practicing neurosurgeon, I’ve seen how hands-on experience and peer collaboration help turn innovation into meaningful advances in patient care,” said Ray Turner, M.D., corporate vice president and chief medical officer, Integra LifeSciences. “Some of the most important conversations in our field happen when surgeons share what they’re seeing in practice, challenge conventional thinking and learn from each other’s experiences. Integra technologies have long been part of my go-to toolkit, and I’m proud to stand behind products I also rely on in my own practice.”

An estimated 13.8 million patients worldwide require neurosurgical intervention each year, underscoring the importance of continued innovation, education, and collaboration across the specialty.¹ Integra’s neurosurgery portfolio includes technologies spanning neurocritical care, cerebrospinal fluid management, dural repair, visualization and tissue resection. The portfolio brings together established technologies such as the CUSA Clarity, celebrating 20 years within Integra’s neurosurgery portfolio, alongside newer innovations such as Aurora® Surgiscope® System.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

¹ Dewan MC, Rattani A, Fieggen G, et al. Global neurosurgery: the current capacity and deficit in the provision of essential neurosurgical care. Executive Summary of the Global Neurosurgery Initiative at the Program in Global Surgery and Social Change. Journal of Neurosurgery. 2018;130(4):1055-1064. doi:10.3171/2017.11.JNS171500.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f5acb50e-642f-413f-b559-d31a2a5e52d6

HOUSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) — Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced the redemption of all $236 million aggregate principal amount outstanding of its 8.625% Senior Notes due 2030 (the “2030 Notes”). The notes are being redeemed at 100% of their principal amount, plus accrued and unpaid interest, using cash on hand.

The redemption further optimizes Weatherford’s capital structure, reduces Weatherford’s gross debt by $236 million, and is expected to reduce annualized cash interest expense by approximately $20 million. Following the redemption, none of Weatherford’s current outstanding debt is scheduled to mature for approximately the next seven years, providing significant financial flexibility to support the Company’s strategic priorities.

Anuj Dhruv, Weatherford’s Executive Vice President and Chief Financial Officer, commented, “This redemption is another step in strengthening our financial foundation and reflects the disciplined approach we continue to take toward capital allocation. Retiring higher-cost debt lowers our interest expense, extends our maturity runway, and gives us greater flexibility to invest in the opportunities that create the most value for Weatherford and our shareholders.”

About Weatherford

Weatherford is a global energy services company that helps customers drill smarter, complete wells more effectively, and maximize production across the entire well lifecycle. With a differentiated portfolio of market-leading solutions, integrated technologies, and a broad global customer footprint across six continents, we blend advanced engineering, digital intelligence, and world-class field expertise to reduce risk, improve performance, and maximize the value of customer assets. Together, we elevate every operation, delivering stronger wells, sharper decisions, and better energy for the world. Visit weatherford.com for more information and connect with us on social media.

Forward-Looking Statement

This news release contains projections and forward-looking statements concerning expectations regarding future financial results. Such statements are only estimates based upon the current beliefs of Weatherford’s management and are subject to significant risks, assumptions, and uncertainties. Should one or more of these risks or uncertainties materialize, or underlying assumptions prove incorrect, actual results may vary materially from those indicated in our forward-looking statements. These risks and uncertainties are more fully described in Weatherford’s reports and registration statements filed with the Securities and Exchange Commission, including the risk factors described in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on any of the Company’s forward-looking statements. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

For Investors:
Luke Lemoine
Senior Vice President, Corporate Development & Investor Relations
+1 713-836-7777
investor.relations@weatherford.com

For Media:
Kelley Hughes
Vice President, Communications, Marketing & Sustainability
media@weatherford.com

ALEXANDRIA, La., Oct. 30, 2026 (GLOBE NEWSWIRE) — Red River Bancshares, Inc. (the “Company”) (Nasdaq: RRBI), the holding company for Red River Bank (the “Bank”), announced today its unaudited financial results for the third quarter of 2026.

Net income for the third quarter of 2026 was $12.6 million, or $1.90 per diluted common share (“EPS”), an increase of $800,000 or 6.8%, compared to $11.8 million, or $1.78 EPS, for the second quarter of 2026, and an increase of $1.8 million, or 16.3%, compared to $10.8 million, or $1.63 EPS, for the third quarter of 2025. For the third quarter of 2026, the quarterly return on assets was 1.48%, and the quarterly return on equity was 12.84%.

Net income for the nine months ended September 30, 2026, was $36.3 million, or $5.49 EPS, an increase of $4.9 million, or 15.8%, compared to $31.3 million, or $4.65 EPS, for the nine months ended September 30, 2025. For the nine months ended September 30, 2026, the return on assets was 1.45%, and the return on equity was 12.73%.

Third Quarter 2026 Performance and Operational Highlights

The third quarter of 2026 financial results included record-high quarterly net income and EPS along with increased loans, deposits, and assets. We also completed our New Orleans market banking center relocation project and continued to execute our plan to expand organically.

• Net income for the third quarter of 2026 was $12.6 million, up $800,000, or 6.8%, from the prior quarter. Net income for the third quarter benefited from a $916,000 increase in net interest income.
• Net interest income increased $916,000, or 3.2%, mainly as a result of higher earning asset balances and one more accrual day in the quarter. Net interest margin fully taxable equivalent (“FTE”) was consistent at 3.61% for the third quarter of 2026 and for the prior quarter.
• As of September 30, 2026, assets were $3.37 billion, up $56.2 million, or 1.7%, from $3.31 billion as of June 30, 2026, as a result of a $56.5 million increase in deposits.
• Deposits totaled $2.96 billion as of September 30, 2026, up $56.5 million, or 1.9%, from $2.91 billion as of June 30, 2026. This increase was primarily due to higher commercial deposit account balances.
• As of September 30, 2026, loans held for investment (“HFI”) were $2.32 billion, up $59.5 million, or 2.6%, from $2.26 billion as of June 30, 2026. In the third quarter of 2026, new loan originations and construction commitment fundings exceeded payments and payoffs.
• In the third quarter of 2026, nonperforming assets (“NPA(s)”) increased $3.0 million, or 113.4%, to $5.6 million, or 0.17% of assets, as of September 30, 2026, primarily due to a commercial relationship that we are actively working to resolve. The provision for loan losses was lower in the third quarter of 2026 compared to the previous quarter.
• We paid a quarterly cash dividend of $0.25 per common share in the third quarter of 2026.
• The 2026 stock repurchase program authorizes us to purchase up to $10.0 million of our outstanding shares of common stock from January 1, 2026 through December 31, 2026. There was no stock repurchase activity between January 1, 2026 and September 30, 2026. As of September 30, 2026, the 2026 stock repurchase program had $10.0 million of available capacity.
• We continued to implement our organic expansion plan with the following projects:
  • In the New Orleans market, we completed our banking center relocation project. We remodeled a portion of the ground floor of the Energy Centre Building on Poydras Street. On July 20, 2026, we relocated the Baronne Street retail banking center and the New Orleans market leadership and lenders to this updated, convenient, and visible location.
  • In the Acadiana market, construction is in process on our second full-service banking center in this market, located on Camellia Boulevard in Lafayette, Louisiana. We expect this location to open in the first quarter of 2027.
  • On October 22, 2026, we purchased a former credit union building located on Gause Boulevard E. in Slidell, Louisiana. We expect to open this location in the first quarter of 2027 as the Bank’s first full-service banking center location in Slidell and our second in the Northshore market.
• In the third quarter of 2026, S&P Global Market Intelligence ranked the Bank within the top 50 best deposit franchises as of June 30, 2026, for banks with assets between $3.0 and $10.0 billion.

Blake Chatelain, President and Chief Executive Officer, stated, “The third quarter of 2026 was very productive, and we are certainly pleased with our financial results. We experienced record-high quarterly net income and EPS, along with solid balance sheet activity and growth.

“In the third quarter of 2026, we saw an increase in loan demand throughout all of our markets, which positively impacted the loan portfolio, as well as the current loan pipeline. The deposit portfolio benefited from higher commercial deposit account balances, combined with the addition of new customers and accounts.

“When 2026 began, we expected a slowly decreasing interest rate environment; however, that shifted to a ‘higher for longer’ rate environment during the summer. Depending on the pace and magnitude of rate changes and the corresponding shift to the yield curve, this environment should benefit the Company. The balance sheet is positioned for a steady, higher rate environment as we price assets at higher rates, while managing the cost of deposits.

“Our organic expansion plan has been very productive in 2026, as we believe it’s a great time to continue investing for future growth. In May 2026, we completed the Northwest market relocation project, and in July 2026, we completed the New Orleans downtown move into the Energy Centre Building. Construction on our new banking center in the Acadiana market is progressing well. We also recently acquired an existing banking center building in Slidell, Louisiana, which we expect to become our second full-service banking center in the Northshore market. We look forward to opening both of these locations in the first quarter of 2027. On the talent front, we have recruited several new bankers across our markets as we continue to expand our Red River Bank team.

“I also want to mention the positive Louisiana economic activity news. There are many significant capital projects that have been announced in the past few years throughout Louisiana. We can identify over $250.0 billion of capital investments in a variety of industries that are in process of being built or in the planning stages. We are excited about the potential financial impact to Louisiana residents, communities, and the state from these investments.

“As we wrap up 2026, we are well-positioned for the future, with solid earnings and robust capital, combined with an expanded banking center network and dedicated bankers. We remain committed to serving our customers, growing, and providing steady financial results for our shareholders.”

Net Interest Income and Net Interest Margin FTE

Net interest income for the third quarter of 2026 was $29.9 million, which was $916,000, or 3.2%, higher than the second quarter of 2026 and benefited from one more accrual day. Net interest income increased due to higher average balances and yields on earning assets, partially offset by a higher cost of deposits and average deposit balances. Interest income on loans increased $1.0 million due to higher average loan balances and yields. For the third quarter of 2026, the average rate on new and renewed loans was 6.47%. Interest income on short-term liquid assets increased $567,000, primarily due to higher average balances. Interest expense increased by $558,000 due to adjusting selected deposit rates in response to rate competition, as well as higher interest-bearing transaction deposit balances.

Net interest margin FTE was 3.61% for the third quarter of 2026, which was consistent with the prior quarter. Net interest margin FTE improved slightly at the end of the third quarter as a result of the higher interest rate environment.

The federal funds rate range was 3.50%-3.75% between December 2025 and September 2026. In September 2026, the Federal Open Market Committee increased the federal funds rate by 25 basis points (“bp(s)”), resulting in a range of 3.75%-4.00%. The market’s expectation is that the federal funds range may increase by another 25 bps in the fourth quarter of 2026. During the fourth quarter of 2026, we project $93.8 million of fixed rate loans at 5.85% to mature, which we expect to redeploy into loans with higher rates. We have $529.5 million of floating rate loans at 6.24%, which we expect to reprice slightly higher. We also expect to receive $24.0 million in securities cash flows at 3.64%, for which we are evaluating reinvestment options as we consider balance sheet management strategies and the forecasted interest rate environment. We project $190.7 million in time deposits at 3.37% to mature, which we expect to renew at higher rates. Selected transaction deposit rates could also be further adjusted in response to rate competition. Depending on balance sheet activity, the interest rate environment, and competition, we expect net interest income and net interest margin FTE to increase slightly in the fourth quarter of 2026.

Noninterest Income

Noninterest income totaled $4.9 million for the third quarter of 2026, up $186,000, or 3.9%, from the previous quarter.

The Small Business Investment Company (“SBIC”) partnerships reported a gain of $112,000 in the third quarter of 2026, compared to a loss of $291,000 in the previous quarter. These results were mainly due to fund value adjustments as an SBIC fund continues its wind-down phase. We expect SBIC income or loss to fluctuate in future quarters.

Mortgage loan income was $698,000 for the third quarter of 2026, down $230,000, or 24.8%, from the previous quarter, due to rising mortgage interest rates reducing mortgage activity.

Debit card income, net, was $1.1 million for the third quarter of 2026, consistent with the previous quarter. The third quarter of 2026 benefited from the receipt of a $50,000 periodic refund from our debit card provider, compared to a $63,000 similar refund in the previous quarter.

Operating Expenses

Operating expenses totaled $18.7 million for the third quarter of 2026, up $408,000, or 2.2%, from the previous quarter.

Personnel expenses totaled $10.9 million for the third quarter of 2026, up $206,000, or 1.9%, from the previous quarter. This increase was primarily due to an increase in headcount and higher personnel-related accruals. As of September 30, 2026 and June 30, 2026, we had 390 and 381 total employees, respectively.

Loan and deposit expenses totaled $426,000 for the third quarter of 2026, up $184,000, or 76.0%, from the previous quarter. The second quarter of 2026 benefited from reimbursement of $82,000 of collection expenses due to the successful resolution of nonaccrual loans.

Occupancy and equipment expenses totaled $1.9 million for the third quarter of 2026, consistent with the previous quarter. The third quarter of 2026 included $46,000 of nonrecurring expenses related to the relocation of banking centers and offices in the Northwest and New Orleans markets.

Legal and professional expenses totaled $487,000 for the third quarter of 2026, down $117,000, or 19.4% from the previous quarter. This decrease was due to lower audit and consulting expenses.

Loans

Loans HFI were $2.32 billion as of September 30, 2026 and $2.26 billion as of June 30, 2026. In the third quarter of 2026, new loan originations and construction commitment fundings exceeded payments and payoffs. As of September 30, 2026, we had $93.8 million of unfunded construction loan commitments, which we expect to fund over time.

Loans HFI by Category
	September 30, 2026						June 30, 2026						Change from June 30, 2026 to September 30, 2026
(dollars in thousands)	Amount			Percent			Amount			Percent			$ Change				% Change
Real estate:
Commercial real estate	$	953,660		41.0	%		$	914,002		40.4	%		$	39,658			4.3	%
One-to-four family residential		647,035		27.9	%			637,566		28.2	%			9,469			1.5	%
Construction and development		223,825		9.6	%			234,190		10.3	%			(10,365	)		(4.4	%)
Commercial and industrial		424,080		18.3	%			399,933		17.7	%			24,147			6.0	%
Tax-exempt		48,640		2.1	%			51,539		2.3	%			(2,899	)		(5.6	%)
Consumer		26,240		1.1	%			26,750		1.1	%			(510	)		(1.9	%)
Total loans HFI	$	2,323,480		100.0	%		$	2,263,980		100.0	%		$	59,500			2.6	%

Asset Quality and Allowance for Credit Losses

NPAs totaled $5.6 million as of September 30, 2026, an increase of $3.0 million, or 113.4%, from June 30, 2026, primarily due to a commercial relationship that we are actively working to resolve. The ratio of NPAs to assets was 0.17% and 0.08% as of September 30, 2026 and June 30, 2026, respectively.

The provision for credit losses for the third quarter of 2026 was $500,000, which was lower than the provision for credit losses of $750,000 for the prior quarter. The decrease was driven by stable charge-off trends and steady local economic conditions affecting the allowance for credit losses (“ACL”) calculation, partially offset by the increase in NPAs. As of September 30, 2026, the ACL was $25.1 million. The ratio of ACL to loans HFI was 1.08% as of September 30, 2026 and 1.09% as of June 30, 2026. The net charge-offs to average loans ratio was 0.01% for the third quarter of 2026 and 0.00% for the prior quarter.

Deposits

As of September 30, 2026, deposits were $2.96 billion, an increase of $56.5 million, or 1.9%, compared to June 30, 2026. The increase in deposits for the third quarter of 2026 was primarily due to higher commercial deposit account balances.

Deposits by Account Type
	September 30, 2026						June 30, 2026						Change from June 30, 2026 to September 30, 2026
(dollars in thousands)	Balance			% of Total			Balance			% of Total			$ Change				% Change
Noninterest-bearing demand deposits	$	915,626		30.9	%		$	910,457		31.3	%		$	5,169			0.6	%
Interest-bearing deposits:
Interest-bearing demand deposits		197,619		6.7	%			183,384		6.3	%			14,235			7.8	%
NOW accounts		443,659		15.0	%			439,093		15.1	%			4,566			1.0	%
Money market accounts		620,283		20.9	%			590,414		20.3	%			29,869			5.1	%
Savings accounts		174,828		5.9	%			173,277		6.0	%			1,551			0.9	%
Time deposits less than or equal to $250,000		399,187		13.5	%			402,423		13.9	%			(3,236	)		(0.8	%)
Time deposits greater than $250,000		210,336		7.1	%			206,019		7.1	%			4,317			2.1	%
Total interest-bearing deposits		2,045,912		69.1	%			1,994,610		68.7	%			51,302			2.6	%
Total deposits	$	2,961,538		100.0	%		$	2,905,067		100.0	%		$	56,471			1.9	%

Deposits by Customer Type
	September 30, 2026						June 30, 2026						Change from June 30, 2026 to September 30, 2026
(dollars in thousands)	Balance			% of Total			Balance			% of Total			$ Change				% Change
Consumer	$	1,389,847		46.9	%		$	1,401,507		48.2	%		$	(11,660	)		(0.8	%)
Commercial		1,349,388		45.6	%			1,269,426		43.7	%			79,962			6.3	%
Public		222,303		7.5	%			234,134		8.1	%			(11,831	)		(5.1	%)
Total deposits	$	2,961,538		100.0	%		$	2,905,067		100.0	%		$	56,471			1.9	%

Stockholders’ Equity

Total stockholders’ equity as of September 30, 2026, was $382.2 million, compared to $384.6 million as of June 30, 2026. The $2.4 million, or 0.6%, decrease in stockholders’ equity during the third quarter of 2026 was attributable to a $13.4 million, net of tax, market adjustment to accumulated other comprehensive loss related to securities and $1.6 million in cash dividends related to a $0.25 per share cash dividend that we paid on September 17, 2026, partially offset by $12.6 million of net income and $129,000 of stock compensation.

Non-GAAP Disclosure

Our accounting and reporting policies conform to United States generally accepted accounting principles (“GAAP”) and the prevailing practices in the banking industry. Certain financial measures used by management to evaluate our operating performance are discussed as supplemental non-GAAP performance measures. In accordance with the Securities and Exchange Commission’s (“SEC”) rules, we classify a financial measure as being a non-GAAP financial measure if that financial measure excludes or includes amounts, or is subject to adjustments that have the effect of excluding or including amounts, that are included or excluded, as the case may be, in the most directly comparable measure calculated and presented in accordance with GAAP as in effect from time to time in the U.S.

Management and the board of directors review tangible common equity, realized common equity, tangible assets, tangible book value per share, realized book value per share, and tangible common equity to tangible assets as part of managing operating performance. However, these non-GAAP financial measures should not be considered in isolation or as a substitute for the most directly comparable or other financial measures calculated in accordance with GAAP. Moreover, the manner we calculate the non-GAAP financial measures that are discussed may differ from that of other companies’ reporting measures with similar names. It is important to understand how other banking organizations calculate and name their financial measures similar to the non-GAAP financial measures discussed by us when comparing such non-GAAP financial measures.

A reconciliation of non-GAAP financial measures to the comparable GAAP financial measures is included within the following financial statement tables.

About Red River Bancshares, Inc.

Red River Bancshares, Inc. is the bank holding company for Red River Bank, a Louisiana state-chartered bank established in 1999 that provides a fully integrated suite of banking products and services tailored to the needs of our commercial and retail customers. Red River Bank operates from a network of 28 banking centers throughout Louisiana and two combined loan and deposit production offices, one each in Lafayette, Louisiana, and Shreveport, Louisiana. Banking centers are located in the following Louisiana markets: Central, which includes the Alexandria metropolitan statistical area (“MSA”); Northwest, which includes the Shreveport-Bossier City MSA; Capital, which includes the Baton Rouge MSA; Southwest, which includes the Lake Charles MSA; the Northshore, which includes the Slidell-Mandeville-Covington MSA; Acadiana, which includes the Lafayette MSA; and New Orleans, which includes the New Orleans-Metairie MSA.

Forward-Looking Statements

Statements in this news release regarding our expectations and beliefs about our future financial performance and financial condition, as well as trends in our business, interest rates, and markets, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “project,” “outlook,” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” The forward-looking statements in this news release are based on current information and on assumptions that we make about future events and circumstances that are subject to a number of risks and uncertainties that are often difficult to predict and beyond our control. As a result of those risks and uncertainties, our actual financial results in the future could differ, possibly materially, from those expressed in or implied by the forward-looking statements contained in this news release and could cause us to make changes to our future plans. Additional information regarding these and other risks and uncertainties to which our business and future financial performance are subject is contained in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent quarterly reports on Form 10-Q, and in other documents that we file with the SEC from time to time. In addition, our actual financial results in the future may differ from those currently expected due to additional risks and uncertainties of which we are not currently aware or which we do not currently view as, but in the future may become, material to our business or operating results. Due to these and other possible uncertainties and risks, readers are cautioned not to place undue reliance on the forward-looking statements contained in this news release or to make predictions based solely on historical financial performance. Any forward-looking statement speaks only as of the date on which it is made, and we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by applicable law. All forward-looking statements, express or implied, included in this news release are qualified in their entirety by this cautionary statement.

Contact:
Isabel V. Carriere, CPA, CGMA
Senior Executive Vice President and Chief Financial Officer
318-561-4023
icarriere@redriverbank.net

FINANCIAL HIGHLIGHTS (UNAUDITED)
		As of and for the Three Months Ended												As of and for the Nine Months Ended
(dollars in thousands, except per share data)		September 30, 2026				June 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
Net Income		$	12,563			$	11,763			$	10,801			$	36,297			$	31,349
Per Common Share Data:
Earnings per share, basic		$	1.91			$	1.79			$	1.63			$	5.51			$	4.67
Earnings per share, diluted		$	1.90			$	1.78			$	1.63			$	5.49			$	4.65
Book value per share		$	58.05			$	58.40			$	53.42			$	58.05			$	53.42
Tangible book value per share(1)		$	57.81			$	58.17			$	53.18			$	57.81			$	53.18
Realized book value per share(1)		$	66.87			$	65.19			$	60.51			$	66.87			$	60.51
Cash dividends per share		$	0.25			$	0.25			$	0.15			$	0.75			$	0.39
Shares outstanding			6,584,106				6,584,696				6,576,609				6,584,106				6,576,609
Weighted average shares outstanding, basic			6,584,119				6,584,696				6,616,826				6,581,962				6,710,902
Weighted average shares outstanding, diluted			6,611,827				6,615,135				6,640,839				6,609,940				6,735,447
Summary Performance Ratios:
Return on average assets			1.48	%			1.43	%			1.34	%			1.45	%			1.32	%
Return on average equity			12.84	%			12.41	%			12.62	%			12.73	%			12.58	%
Net interest margin			3.56	%			3.56	%			3.38	%			3.53	%			3.29	%
Net interest margin FTE			3.61	%			3.61	%			3.43	%			3.58	%			3.34	%
Efficiency ratio			53.71	%			54.25	%			56.06	%			53.46	%			56.15	%
Loans HFI to deposits ratio			78.46	%			77.93	%			76.55	%			78.46	%			76.55	%
Noninterest-bearing deposits to deposits ratio			30.92	%			31.34	%			32.37	%			30.92	%			32.37	%
Noninterest income to average assets			0.58	%			0.58	%			0.62	%			0.57	%			0.63	%
Operating expense to average assets			2.20	%			2.22	%			2.22	%			2.17	%			2.18	%
Summary Credit Quality Ratios:
NPAs to assets			0.17	%			0.08	%			0.08	%			0.17	%			0.08	%
Nonperforming loans to loans HFI			0.24	%			0.11	%			0.11	%			0.24	%			0.11	%
ACL to loans HFI			1.08	%			1.09	%			1.05	%			1.08	%			1.05	%
Net charge-offs to average loans			0.01	%			0.00	%			0.00	%			0.01	%			0.02	%
Capital Ratios:
Stockholders’ equity to assets			11.35	%			11.61	%			10.93	%			11.35	%			10.93	%
Tangible common equity to tangible assets(1)			11.31	%			11.57	%			10.89	%			11.31	%			10.89	%
Total risk-based capital to risk-weighted assets			18.72	%			18.76	%			18.18	%			18.72	%			18.18	%
Tier I risk-based capital to risk-weighted assets			17.68	%			17.71	%			17.17	%			17.68	%			17.17	%
Common equity Tier I capital to risk-weighted assets			17.68	%			17.71	%			17.17	%			17.68	%			17.17	%
Tier I risk-based capital to average assets			12.82	%			12.77	%			12.17	%			12.82	%			12.17	%

⁽¹⁾ Non-GAAP financial measure. Calculations of this measure and reconciliations to GAAP are included in the schedules accompanying this release.

RED RIVER BANCSHARES, INC.
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands)	September 30, 2026				June 30, 2026				March 31, 2026				December 31, 2025				September 30, 2025
ASSETS
Cash and due from banks	$	29,044			$	33,327			$	36,677			$	25,685			$	33,651
Interest-bearing deposits in other banks		176,004				162,069				173,845				187,707				127,404
Securities available-for-sale, at fair value		601,571				617,016				638,729				647,310				636,679
Securities held-to-maturity, at amortized cost		115,922				118,356				120,609				122,619				124,853
Equity securities, at fair value		2,887				3,000				3,012				3,031				3,019
Nonmarketable equity securities		2,459				2,442				2,425				2,407				2,387
Loans held for sale		1,699				2,512				3,951				3,148				3,260
Loans held for investment		2,323,480				2,263,980				2,254,546				2,248,669				2,173,073
Allowance for credit losses		(25,119	)			(24,771	)			(24,051	)			(23,399	)			(22,801	)
Premises and equipment, net		61,814				60,136				60,516				59,270				58,573
Accrued interest receivable		10,682				10,317				11,352				11,131				10,281
Bank-owned life insurance		31,964				31,724				31,488				31,267				31,041
Intangible assets		1,546				1,546				1,546				1,546				1,546
Right-of-use assets		976				1,326				1,407				1,487				1,564
Other assets		32,622				28,345				30,548				29,032				29,833
Total Assets	$	3,367,551			$	3,311,325			$	3,346,600			$	3,350,910			$	3,214,363
LIABILITIES
Noninterest-bearing deposits	$	915,626			$	910,457			$	916,413			$	913,868			$	918,974
Interest-bearing deposits		2,045,912				1,994,610				2,029,522				2,049,544				1,919,809
Total Deposits		2,961,538				2,905,067				2,945,935				2,963,412				2,838,783
Accrued interest payable		6,069				6,349				6,025				6,128				6,681
Lease liabilities		1,027				1,383				1,465				1,544				1,623
Accrued expenses and other liabilities		16,736				13,975				19,849				14,676				15,965
Total Liabilities		2,985,370				2,926,774				2,973,274				2,985,760				2,863,052
COMMITMENTS AND CONTINGENCIES		—				—				—				—				—
STOCKHOLDERS’ EQUITY
Preferred stock, no par value		—				—				—				—				—
Common stock, no par value		27,591				27,591				27,591				27,543				27,543
Additional paid-in capital		3,602				3,473				3,329				3,217				3,105
Retained earnings		409,092				398,175				388,058				377,731				367,302
Accumulated other comprehensive income (loss)		(58,104	)			(44,688	)			(45,652	)			(43,341	)			(46,639	)
Total Stockholders’ Equity		382,181				384,551				373,326				365,150				351,311
Total Liabilities and Stockholders’ Equity	$	3,367,551			$	3,311,325			$	3,346,600			$	3,350,910			$	3,214,363

RED RIVER BANCSHARES, INC.
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
		For the Three Months Ended												For the Nine Months Ended
(in thousands)		September 30, 2026				June 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
INTEREST AND DIVIDEND INCOME
Interest and fees on loans		$	33,234			$	32,234			$	30,612			$	97,013			$	88,383
Interest on securities			5,671				5,778				5,425				17,293				15,428
Interest on deposits in other banks			1,861				1,294				2,079				4,892				6,803
Dividends on stock			31				17				33				66				73
Total Interest and Dividend Income			40,797				39,323				38,149				119,264				110,687
INTEREST EXPENSE
Interest on deposits			10,914				10,356				11,263				32,010				33,372
Total Interest Expense			10,914				10,356				11,263				32,010				33,372
Net Interest Income			29,883				28,967				26,886				87,254				77,315
Provision for credit losses			500				750				650				2,000				1,550
Net Interest Income After Provision for Credit Losses			29,383				28,217				26,236				85,254				75,765
NONINTEREST INCOME
Service charges on deposit accounts			1,430				1,388				1,442				4,213				4,160
Debit card income, net			1,062				1,067				852				3,045				2,925
Mortgage loan income			698				928				652				2,231				1,749
Brokerage income			1,015				874				1,131				2,827				3,446
Loan and deposit income			456				521				393				1,475				1,270
Bank-owned life insurance income			241				236				224				697				661
Gain (Loss) on equity securities			(113	)			(13	)			28				(144	)			82
Gain (Loss) on sale and call of securities			—				(22	)			—				(22	)			—
SBIC income (loss)			112				(291	)			(75	)			(283	)			252
Other income (loss)			23				50				378				155				470
Total Noninterest Income			4,924				4,738				5,025				14,194				15,015
OPERATING EXPENSES
Personnel expenses			10,917				10,711				10,511				32,145				30,750
Occupancy and equipment expenses			1,939				1,935				1,846				5,758				5,394
Technology expenses			978				955				831				2,796				2,486
Advertising			344				324				293				995				911
Other business development expenses			600				641				531				1,790				1,544
Data processing expense			783				758				724				1,918				1,734
Other taxes			559				553				604				1,671				1,825
Loan and deposit expenses			426				242				356				771				816
Legal and professional expenses			487				604				605				1,621				1,849
Regulatory assessment expenses			450				409				430				1,275				1,209
Other operating expenses			1,211				1,154				1,158				3,490				3,326
Total Operating Expenses			18,694				18,286				17,889				54,230				51,844
Income Before Income Tax Expense			15,613				14,669				13,372				45,218				38,936
Income tax expense			3,050				2,906				2,571				8,921				7,587
Net Income		$	12,563			$	11,763			$	10,801			$	36,297			$	31,349

RED RIVER BANCSHARES, INC.
NET INTEREST INCOME AND NET INTEREST MARGIN (UNAUDITED)
	For the Three Months Ended
	September 30, 2026										June 30, 2026
(dollars in thousands)	Average Balance Outstanding				Interest Income/ Expense			Average Yield/ Rate			Average Balance Outstanding				Interest Income/ Expense			Average Yield/ Rate
Assets
Interest-earning assets:
Loans(1,2)	$	2,299,635			$	33,234		5.66	%		$	2,262,588			$	32,234		5.64	%
Securities – taxable		604,138				4,713		3.12	%			620,153				4,808		3.10	%
Securities – tax-exempt		178,077				958		2.15	%			181,703				970		2.14	%
Interest-bearing deposits in other banks		198,578				1,861		3.67	%			141,318				1,294		3.63	%
Nonmarketable equity securities		2,444				31		5.01	%			2,427				17		2.81	%
Total interest-earning assets		3,282,872			$	40,797		4.88	%			3,208,189			$	39,323		4.86	%
Allowance for credit losses		(25,022	)									(24,334	)
Noninterest-earning assets		116,272										120,368
Total assets	$	3,374,122									$	3,304,223
Liabilities and Stockholders’ Equity
Interest-bearing liabilities:
Interest-bearing transaction deposits	$	1,404,032			$	5,691		1.61	%		$	1,349,934			$	5,192		1.54	%
Time deposits		608,435				5,223		3.41	%			607,580				5,164		3.41	%
Total interest-bearing deposits		2,012,467				10,914		2.15	%			1,957,514				10,356		2.12	%
Other borrowings		—				—		—	%			—				—		—	%
Total interest-bearing liabilities		2,012,467			$	10,914		2.15	%			1,957,514			$	10,356		2.12	%
Noninterest-bearing liabilities:
Noninterest-bearing deposits		950,293										945,138
Accrued interest and other liabilities		23,282										21,481
Total noninterest-bearing liabilities		973,575										966,619
Stockholders’ equity		388,080										380,090
Total liabilities and stockholders’ equity	$	3,374,122									$	3,304,223
Net interest income					$	29,883									$	28,967
Net interest spread								2.73	%									2.74	%
Net interest margin								3.56	%									3.56	%
Net interest margin FTE(3)								3.61	%									3.61	%
Cost of deposits								1.46	%									1.43	%
Cost of funds								1.32	%									1.29	%

⁽¹⁾ Includes average outstanding balances of loans held for sale of $2.9 million and $4.7 million for the three months ended September 30, 2026 and June 30, 2026, respectively.
⁽²⁾ Nonaccrual loans are included as loans carrying a zero yield.
⁽³⁾ Net interest margin FTE includes an FTE adjustment using a 21.0% federal income tax rate on tax-exempt securities and tax-exempt loans.

RED RIVER BANCSHARES, INC.
NET INTEREST INCOME AND NET INTEREST MARGIN (UNAUDITED)
	For the Nine Months Ended
	September 30, 2026										September 30, 2025
(dollars in thousands)	Average Balance Outstanding				Interest Income/ Expense			Average Yield/ Rate			Average Balance Outstanding				Interest Income/ Expense			Average Yield/ Rate
Assets
Interest-earning assets:
Loans(1,2)	$	2,272,701			$	97,013		5.63	%		$	2,121,894			$	88,383		5.50	%
Securities – taxable		617,853				14,393		3.11	%			573,645				12,492		2.90	%
Securities – tax-exempt		180,907				2,900		2.14	%			187,210				2,936		2.09	%
Interest-bearing deposits in other banks		177,271				4,892		3.64	%			205,182				6,803		4.37	%
Nonmarketable equity securities		2,427				66		3.64	%			2,350				73		4.12	%
Total interest-earning assets		3,251,159			$	119,264		4.85	%			3,090,281			$	110,687		4.73	%
Allowance for credit losses		(24,339	)									(22,069	)
Noninterest-earning assets		121,197										106,639
Total assets	$	3,348,017									$	3,174,851
Liabilities and Stockholders’ Equity
Interest-bearing liabilities:
Interest-bearing transaction deposits	$	1,397,896			$	16,440		1.57	%		$	1,308,321			$	16,877		1.72	%
Time deposits		607,995				15,570		3.42	%			598,776				16,495		3.68	%
Total interest-bearing deposits		2,005,891				32,010		2.13	%			1,907,097				33,372		2.34	%
Other borrowings		—				—		—	%			—				—		—	%
Total interest-bearing liabilities		2,005,891			$	32,010		2.13	%			1,907,097			$	33,372		2.34	%
Noninterest-bearing liabilities:
Noninterest-bearing deposits		937,804										910,743
Accrued interest and other liabilities		23,243										23,766
Total noninterest-bearing liabilities		961,047										934,509
Stockholders’ equity		381,079										333,245
Total liabilities and stockholders’ equity	$	3,348,017									$	3,174,851
Net interest income					$	87,254									$	77,315
Net interest spread								2.72	%									2.39	%
Net interest margin								3.53	%									3.29	%
Net interest margin FTE(3)								3.58	%									3.34	%
Cost of deposits								1.45	%									1.58	%
Cost of funds								1.32	%									1.44	%

⁽¹⁾ Includes average outstanding balances of loans held for sale of $3.4 million and $2.8 million for the nine months ended September 30, 2026 and 2025, respectively.
⁽²⁾ Nonaccrual loans are included as loans carrying a zero yield.
⁽³⁾ Net interest margin FTE includes an FTE adjustment using a 21.0% federal income tax rate on tax-exempt securities and tax-exempt loans.

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (UNAUDITED)
(dollars in thousands, except per share data)	September 30, 2026				June 30, 2026				September 30, 2025
Tangible common equity
Total stockholders’ equity	$	382,181			$	384,551			$	351,311
Adjustments:
Intangible assets		(1,546	)			(1,546	)			(1,546	)
Tangible common equity (non-GAAP)	$	380,635			$	383,005			$	349,765
Realized common equity
Total stockholders’ equity	$	382,181			$	384,551			$	351,311
Adjustments:
Accumulated other comprehensive (income) loss		58,104				44,688				46,639
Realized common equity (non-GAAP)	$	440,285			$	429,239			$	397,950
Common shares outstanding		6,584,106				6,584,696				6,576,609
Book value per share	$	58.05			$	58.40			$	53.42
Tangible book value per share (non-GAAP)	$	57.81			$	58.17			$	53.18
Realized book value per share (non-GAAP)	$	66.87			$	65.19			$	60.51
Tangible assets
Total assets	$	3,367,551			$	3,311,325			$	3,214,363
Adjustments:
Intangible assets		(1,546	)			(1,546	)			(1,546	)
Tangible assets (non-GAAP)	$	3,366,005			$	3,309,779			$	3,212,817
Stockholders’ equity to assets		11.35	%			11.61	%			10.93	%
Tangible common equity to tangible assets (non-GAAP)		11.31	%			11.57	%			10.89	%

• Project Recognized by UNESCO IITE, UIL, and Shanghai Open University for AI-Driven Education Innovation
• Proprietary AI English Go and CEPA Platforms Combine Multi-Agent Architecture with Automated Diagnostics and Teacher Review
• System Scaled to Nearly 100 Institutions, Supporting Over 40,000 Students and Three Accredited Shanghai University Courses
  

SINGAPORE and HONG KONG, Oct. 30, 2026 (GLOBE NEWSWIRE) — NETCLASS TECHNOLOGY INC (Nasdaq: NTCL; the “Company” or “NetClass”), a B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, Singapore and Tokyo, today announced that its case study on multi-agent foreign language education received the Outstanding Case Award at the 2026 Digital Lifelong Learning International Conference.

The conference was held on October 16-17, 2026, at Shanghai Open University, co-organized by Shanghai Open University, the UNESCO Institute for Lifelong Learning (UIL), and the UNESCO Institute for Information Technologies in Education (UNESCO IITE). NetClass’s case, titled “Multi-Agent Collaboration-Driven Foreign Language Teaching Assessment and Personalized Learning Support Practice,” was selected from a nationwide pool of submissions on AI-empowered smart learning ecosystems.

The recognized initiative applies multi-agent architectures and large language models (LLMs) to common constraints in conventional foreign language instruction, such as limited oral practice, delayed grading feedback, and the difficulty of converting evaluation metrics into tailored lesson plans. Built on the Company’s proprietary AI English Go instruction system and CEPA assessment engine, the platform coordinates specialized agents to analyze discrete language components, including pronunciation, vocabulary, grammar, discourse structure, and pragmatic usage. To address common LLM output variance and explainability issues, the software incorporates confidence score fusion, anomaly flagging, dynamic routing, and human instructor review for open-ended assignments like oral dialogue and composition.

At the conference, NetClass Deputy General Manager, Jing Wang, presented the case study and participated in discussions with academic researchers and industry peers on practical integration methods for AI in higher education.

“Receiving this recognition from prestigious institutions like UNESCO IITE and UIL validates our conviction that multi-agent AI architectures represent the future of educational technology,” said Dr. Jianbiao Dai, Chairman and Chief Executive Officer of NetClass. “Language teachers frequently spend excessive hours on routine error correction rather than direct instruction. By assigning discrete evaluation tasks to specialized software agents with human-in-the-loop controls, our platform provides reliable, diagnostic feedback that faculty can use in real time. This award fuels our strategic ambition to continuously push the boundaries of applied AI, expanding our multi-agent framework across broader subjects, diverse languages, and new global markets to fundamentally redefine digital education.”

About NETCLASS TECHNOLOGY INC
NETCLASS TECHNOLOGY INC is a B2B smart education specialist with offices in Shanghai, Hong Kong, Singapore, and Tokyo, providing innovative IT solutions to schools, training institutions, corporations, public agencies, and other organizations. The Company’s services include SaaS subscription services and application software development, and, through its joint venture, interactive AI companion smart hardware, with solutions spanning teaching and campus management, online teaching, examinations, epidemic prevention, data storage, EDC (Education Credit) blockchain systems, and lecturer evaluation services. The Company’s mission is to deliver reliable, high-quality products that drive sustainable growth for our customers. For more information, please visit the Company’s website: https://ir.netclasstech.com

Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:
NETCLASS TECHNOLOGY INC
Investor Relations
Email: ir@netclasstech.com

Jackson Lin
LLYC
Email: jian.lin@llyc.global

WEST PALM BEACH, FL, Oct. 30, 2026 (GLOBE NEWSWIRE) — AVAX One Technology Ltd. (Nasdaq: AVX) (“AVAX One” or the “Company”), today announced that it will host a conference call on Thursday, November 12, 2026 at 5:00 p.m. Eastern time to discuss its financial and operating results for the third quarter ended September 30, 2026. The Company plans to release its financial results in a press release prior to the call.

AVAX One’s management team will host the conference call, followed by a question-and-answer period.

Conference Call and Webcast Details

Date: Thursday, November 12, 2026
Time: 5:00 p.m. ET
Toll-free dial-in number: (800) 715-9871
International dial-in number: (646) 307-1963
Conference ID: 3001159
Webcast: AVAX One’s Q3 2026 Earnings Conference Call

Participants can also access the Company’s earnings call using the call me option here for instant telephone access to the event, which will be active approximately 15 minutes before the scheduled start time.

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

The conference call will also be available for replay on the investor relations section of the Company’s website at www.avax-one.com.

About AVAX One Technology Ltd.

AVAX One Technology Ltd. (NASDAQ: AVX) is a digital infrastructure company accelerating the transition to an onchain financial economy. The Company maintains a strategic Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation. It also operates bitcoin mining facilities and develops modular data centers. These three pillars give public market investors unique exposure to both the onchain economy and the digital infrastructure layer. For more information, please visit www.avax-one.com.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
AVX@elevate-ir.com

Media Contact
Ethan Lyle
Prospero
avax-one@prospero.agency

MARKHAM, Ontario, Oct. 30, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company“) (TSX: SIA) announced today that it has completed its previously disclosed $170.7 million acquisition of Stonemont On the Park (“Stonemont”), a 305-suite retirement residence in Ottawa, Ontario.

Stonemont is a newly built, nearly 100% occupied retirement residence that opened in 2024. It offers a broad range of senior living and care options, from fully independent seniors’ apartments to supportive and assisted living with enhanced care services. The transaction includes an additional $10.0 million earnout contingent upon exceeding certain financial targets.

Sienna financed the acquisition with available cash on hand.

“The addition of Stonemont highlights the quality and scale of the opportunities available to us as we continue to grow our Company,” said Nitin Jain, President and Chief Executive Officer. “Since the beginning of 2025, we have added approximately $1.2 billion in assets through acquisitions and developments, with each addition reflecting our strategy of expanding in attractive markets and complementing our growing platform with high-quality assets.”

About Sienna Senior Living

Sienna Senior Living Inc. (TSX: SIA) offers a full range of seniors’ living options, including independent living, assisted living and memory care under its Aspira retirement brand, long-term care, and specialized programs and services. Sienna’s approximately 15,500 employees are passionate about cultivating happiness in daily life. For more information, please visit www.siennaliving.ca.

Forward-Looking Statements

Certain of the statements contained in this news release are forward-looking statements and are provided for the purpose of presenting information about management’s current expectations and plans relating to the future. Readers are cautioned that such statements may not be appropriate for other purposes. These statements generally use forward-looking words, such as “anticipate,” “continue,” “could,” “expect,” “may,” “will,” “estimate,” “believe,” “goals”, “target” or other similar words and are based on the Company’s expectations, estimates, forecasts and projections. These statements are subject to significant known and unknown risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such statements and, accordingly, should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. The forward-looking statements in this news release are based on information currently available and what management currently believes are reasonable assumptions. The Company does not undertake any obligation to publicly update or revise any forward-looking statements except as may be required by applicable law.

FOR FURTHER INFORMATION, PLEASE CONTACT:

David Hung
Chief Financial Officer and Executive Vice President, Investments
(905) 489-0258
david.hung@siennaliving.ca

Nancy Webb
Executive Vice President, Corporate Affairs and Marketing
(905) 477-4006 ext. 3030
nancy.webb@siennaliving.ca

Announces Regular Quarterly Cash Dividend of $0.20 Per Share

• Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $3.7 million or 18% compared to the second quarter of 2026.
• Reports GAAP diluted EPS of $0.51 and non-GAAP diluted EPS of $0.55 for the third quarter of 2026 compared to GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.47 for the second quarter of 2026.
• Declares a regular quarterly cash dividend of $0.20 per share of common stock for the third quarter of 2026, payable on November 27, 2026.

ORLANDO, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2026. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures.

“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected. Quarterly bookings also set new records, driven by another record number of monitor units being booked and a 45% year-over-year increase in domestic pump channels booked. Of special note is that over 70% of pump bookings in the quarter were for our ‘quad stack’ configuration of four pumps on a single IV pole, as customers continue to accelerate their replacement of our older model and standardize on this setup which is a doubling of pump channels previously available at each MRI. With record bookings and rapidly building 3870 momentum, we believe we are well positioned for a strong finish to the year,” said Roger Susi, President and Chief Executive Officer of Iradimed.

“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61. We revise our guidance for the full-year 2026, expecting to report revenue of $91.6 million to $93.1 million from $91.0 million to $96.0 million, and GAAP diluted earnings per share to $1.90 to $1.94 from $1.90 to $2.05 and non-GAAP diluted earnings per share to $2.07 to $2.11 from $2.06 to $2.21,” added Mr. Susi.

The Company’s board of directors declared a regular quarterly cash dividend of $0.20 per share of our outstanding common stock. The dividend is payable to stockholders of record as of the close of business on November 13, 2026 and will be paid on November 27, 2026.

Three Months Ended September 30, 2026

For the three months ended September 30, 2026, the Company reported revenue of $24.2 million, compared to $21.2 million for the comparable period of 2025, which increased by $3.0 million or 14%. The Company reported net income of $6.5 million, compared to $5.6 million for the comparable period of 2025, which increased by 17%. Earnings per share increased by $0.08 per diluted share or 17% to $0.51 per diluted share, for the three months ended September 30, 2026, compared to $0.43 per diluted share for the same period of 2025.

For the three months ended September 30, 2026, non-GAAP net income was $7.1 million, an increase of 17% compared to $6.1 million for the same period in 2025. Non-GAAP net income excludes stock-based compensation expense, net of tax benefit, of $0.6 million for the third quarter of 2026 and $0.5 million for the third quarter of 2025. On a non-GAAP basis, net income per diluted share was $0.55 for the three months ended September 30, 2026, compared to $0.47 per diluted share for the comparable period of 2025, which increased by 17%.

Nine Months Ended September 30, 2026

For the nine months ended September 30, 2026, the Company reported revenue of $66.6 million, compared to $61.1 million for the comparable period of 2025, which increased by $5.5 million or 9%. The Company reported net income of $17.5 million, compared to $16.0 million for the comparable period of 2025, which increased by 9%. Earnings per share increased by $0.12 per diluted share or 10% to $1.37 per diluted share, for the nine months ended September 30, 2026, compared to $1.25 per diluted share for the same period of 2025.

For the nine months ended September 30, 2026, non-GAAP net income was $19.3 million, an increase of 9% compared to $17.8 million for the same period in 2025. Non-GAAP net income excludes stock-based compensation expense, net of tax benefit, of $1.8 million for each of the nine-month periods presented. On a non-GAAP basis, net income per diluted share was $1.50 for the nine months ended September 30, 2026, compared to $1.39 per diluted share for the comparable period of 2025, which increased by 8% .

Revenue Information:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
(in thousands)	(unaudited)						(unaudited)
Devices:
MRI Compatible Intravenous (“IV”) Infusion Pump Systems	$	8,687		$	8,334		$	22,779		$	22,521
MRI Compatible Patient Vital Signs Monitoring Systems		8,006			6,872			21,778			19,361
Ferro Magnetic Detection Systems		483			378			1,861			1,278
Total devices revenue		17,176			15,584			46,418			43,160
Amortization of extended maintenance agreements		801			613			2,218			1,766
Disposables		4,981			4,131			14,659			13,281
Services and other		1,245			874			3,353			2,915
Total revenue	$	24,203		$	21,202		$	66,648		$	61,122

For the three months ended September 30, 2026 and 2025, domestic sales were 82% and 85% of total revenue, respectively. For the three months ended September 30, 2026, the gross profit margin was 76% compared to 78% for the comparable period of 2025.

For the nine months ended September 30, 2026 and 2025, domestic sales were 82% and 85% of total revenue, respectively. For the nine months ended September 30, 2026, the gross profit margin was 76% compared to 77% for the comparable period of 2025.

Cash Flow from Operations

For the three months ended September 30, 2026, cash flow from operations was $7.0 million, consistent with $7.0 million for the comparable period of 2025. For the three months ended September 30, 2026, cash provided by operations reflected higher net income and a smaller increase in accounts receivable, partially offset by higher income tax payments, increased inventory purchases, and prepaid expenses.. See the compilation of non-GAAP free cash flow in the table later in this release.

For the nine months ended September 30, 2026, cash flow from operations was $21.2 million, compared to $19.0 million for the comparable period of 2025, an increase of 12%. For the nine months ended September 30, 2026, cash provided by operations reflected higher net income, a smaller increase in accounts receivable, and higher accounts payable, partially offset by higher income tax payments, increased inventory purchases, and a smaller increase in deferred revenue. See the compilation of non-GAAP free cash flow in the table later in this release.

Financial Guidance

For the fourth quarter of 2026, the Company expects revenue of $25.0 million to $26.5 million, GAAP diluted earnings per share of $0.53 to $0.57, and non-GAAP diluted earnings per share of $0.57 to $0.61. For the full year 2026, the Company expects to report revenue of $91.6 million to $93.1 million, GAAP diluted earnings per share of $1.90 to $1.94, and non-GAAP diluted earnings per share of $2.07 to $2.11.

The Company’s non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax expense. The Company expects stock-based compensation expense, net of tax, to be approximately $2.5 million and $0.6 million for the full year and third quarter of 2026, respectively.

Presentation of Amounts

Amounts discussed in this press release are presented in millions, rounded to one decimal place, and amounts in the accompanying financial tables are presented in thousands, except per share data. Percentage changes are calculated using the amounts in thousands presented in the tables, and per share amounts are calculated using unrounded amounts. As a result, percentages recalculated using the rounded amounts in millions may differ from those presented.

Use of Non-GAAP Financial Measures

The Company believes using non-GAAP net income, non-GAAP net income per share-diluted, and free cash flow is helpful to our investors. These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These non-GAAP measures are intended to provide the reader with additional supplemental perspectives on operating results, performance trends, and financial condition. Non-GAAP financial measures are not a substitute for GAAP measures; they should be read and used in conjunction with the Company’s GAAP financial information. Because non-GAAP financial measures presented in this release are not measurements determined in accordance with GAAP and are susceptible to varying calculations, these non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures presented by other companies.

We calculate non-GAAP net income as net income excluding:

(1)  Stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allows for meaningful comparisons between our operating results from period to period;

(2)  Operating expenses, net of tax, that we believe are not indicative of the Company’s ongoing core operating performance; and

(3)  Infrequent income tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes.

We calculate free cash flow as net cash provided by operating activities, less net cash used in investing activities for the development of internal software and purchases of property and equipment.

We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our stockholders through various means.

Our non-GAAP financial measures are important tools for financial and operational decision-making and for evaluating our ongoing core operating results.

A reconciliation of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of
operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with GAAP and are not indicative of net income or cash provided by operating activities.

Conference Call

The Company has scheduled a conference call to discuss this release beginning at 11:00 a.m. Eastern Time, October 30, 2026. Individuals interested in listening to the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7e9cb633a38e45258f691f2b6d592419

Once registered, a dial-in number, a unique PIN, and instructions will be provided to participants.

The conference call will also be available in real-time via the Internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the call’s completion.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump systems (3860 and 3870) have a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solutions provide a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

For more information, please visit www.iradimed.com.

Forward-Looking Statements

This release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, that address activities that the Company assumes, plans, expects, believes, intends, projects, indicates, estimates or anticipates (and other similar expressions) will, should or may occur in the future are forward-looking statements, including statements relating to financial guidance, future quarterly cash dividends, operational issues meeting demand, commercialization, timing and expected revenue ramping of our next-generation 3870 MRI compatible IV infusion pump, and the Company’s strategic plans, objectives, and intentions. The forward-looking statements are based on management’s current belief, based on currently available information, as to the outcome and timing of future events. The forward-looking statements involve risks and uncertainties, including, among others, that our business plans may change as circumstances warrant.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management’s current estimates, projections, expectations, or beliefs, and which involve
risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to: our ability to obtain or maintain regulatory approvals and comply with applicable regulations, including 510(k) clearances for our products and product candidates, the outcome of inspections conducted by the U.S. Food & Drug Administration (the “FDA”) or other regulatory bodies, additional actions by or requests from the FDA or other regulatory bodies, and unanticipated costs or delays associated with the resolution of such matters; our reliance on a limited number of products and our ability to identify and pursue development of additional products; our ability to retain key management, marketing and scientific personnel, and to attract and retain additional qualified personnel; our expectations regarding the sales and marketing of our products and services; our expectations regarding the integrity of our supply chain; the potential for adverse application of applicable laws and regulations on our operations; our expectations for market acceptance of our new products; the potential for exposure to product liability claims and our marketed products to be withdrawn due to recalls or adverse events; our ability to prepare, file, prosecute, maintain, defend against infringement of, and enforce patent claims and other intellectual property rights on our products; the implementation of our business strategies; our financial performance and how it may be interpreted by securities analysts and investors; our ability to compete with existing competitors and new market entrants; difficulties or delays in developing, manufacturing, or marketing our products and services; changes in laws or in their interpretation or application, and the risk of non-compliance; cost-containment efforts of our customers, purchasing groups, third-party payers and governmental organizations; costs associated with protecting our trade secrets and enforcing our patent, copyright and trademark rights, including the risk of successful challenges to the validity of such rights; costs or claims resulting from errors or defects in our manufacturing that may injure persons or damage property, including costs from remediation efforts or recalls; the results or timing of any commercial disputes, patent infringement claims, other legal proceedings, or government investigations; interruptions in our ability to manufacture our products, or the unavailability or increased cost of key components or raw materials; the risk that third parties may fail to meet their contractual obligations, which could disrupt our operations or adversely affect our financial results; the effects of government-mandated healthcare reform; the impact on our operations and financial results of public health emergencies, including natural disasters, and policies and actions by governments or other third parties; breaches or failures of our or our vendors’ or customers’ information technology systems, including by cyberattack, data leakage, or unauthorized access; the risks associated with the integration of artificial intelligence (“AI”) or machine learning (“ML”) into our products or business, including algorithmic errors or bias, uncertain regulatory requirements applicable to AI-enabled medical devices, data privacy and security concerns arising from the use of AI or ML, and potential liability arising from AI-driven product decisions or recommendations; the loss of one or more key customers or suppliers, or a default by any such party; unfavorable changes to the terms of key customer or supplier relationships; weakening of economic conditions that could adversely affect demand for our products; changes in tax rates, interest rates or inflationary pressures on the U.S. and global economies; geopolitical risks, including international conflicts and political instability, which could lead to increased market volatility; and other risks detailed in our filings with the United States Securities and Exchange Commission (the “SEC”). You should consider the forward-looking statements contained in this press release in light of the risk factors and other information set forth under Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A, “Risk Factors” of the Company’s Quarterly Reports on Form 10-Q, and Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as those otherwise described or updated from time to time in our other filings with the SEC. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and the Company undertakes no commitment to publicly update or revise the forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable law.

IRADIMED CORPORATION CONDENSED BALANCE SHEETS (in thousands)
	September 30,			December 31,
	2026			2025
	(unaudited)			(audited)
ASSETS
Current assets:
Cash and cash equivalents	$	63,288		$	51,159
Other current assets		29,512			30,044
Total current assets		92,800			81,203
Property and equipment, net		24,076			23,856
Other assets		4,194			3,717
Total assets	$	121,070		$	108,776
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	2,419		$	1,820
Deferred revenue		3,572			2,871
Other current liabilities		4,332			5,489
Total current liabilities		10,323			10,180
Deferred revenue, non-current		4,293			3,978
Total liabilities		14,616			14,158
Stockholders’ equity:
Total stockholders’ equity		106,454			94,618
Total liabilities and stockholders’ equity	$	121,070		$	108,776

IRADIMED CORPORATION CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (in thousands, except per share data)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Revenue	$	24,203		$	21,202		$	66,648		$	61,122
Cost of revenue		5,747			4,708			16,219			13,830
Gross profit		18,456			16,494			50,429			47,292
Operating expenses:
General and administrative		4,533			4,356			12,967			13,246
Sales and marketing		4,909			4,631			13,207			12,817
Research and development		875			674			2,489			2,176
Total operating expenses		10,317			9,661			28,663			28,239
Income from operations		8,139			6,833			21,766			19,053
Other income, net		529			464			1,559			1,517
Income before provision for income taxes		8,668			7,297			23,325			20,570
Provision for income tax expense		2,162			1,721			5,783			4,532
Net income	$	6,506		$	5,576		$	17,542		$	16,038
Net income per share:
Basic	$	0.51		$	0.44		$	1.37		$	1.26
Diluted	$	0.51		$	0.43		$	1.37		$	1.25
Weighted average shares outstanding:
Basic		12,787			12,721			12,784			12,717
Diluted		12,877			12,860			12,873			12,842

IRADIMED CORPORATION RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (Unaudited) (in thousands, except per share data)
Non-GAAP Net Income and Diluted EPS
	Three Months Ended September 30,							Nine Months Ended September 30,
	2026			2025				2026			2025
Net income	$	6,506		$	5,576			$	17,542		$	16,038
Excluding:
Stock-based compensation expense, net of tax benefit		616			527				1,799			1,760
Non-GAAP net income	$	7,122		$	6,103			$	19,341		$	17,798
Weighted-average shares outstanding – diluted		12,877			12,860				12,873			12,842
Non-GAAP net income per share – diluted	$	0.55		$	0.47			$	1.50		$	1.39

Non-GAAP Free Cash Flow
		Three Months Ended September 30,					Nine Months Ended September 30,
		2026		2025			2026			2025
Net cash provided by operating activities	$	6,996		$	6,986		$	21,227		$	19,025
Less:
Capital Expenditures		212			1,264	1		1,124			8,005	1
Free cash flow	$	6,784		$	5,722		$	20,103		$	11,020
1 For the three and nine months ended September 30, 2025, capital expenditures include approximately $1.3 million and $6.8 million respectively, related to the construction of a new corporate office and manufacturing facility completed in 2025.

Media Contact:
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com

• 1-for-60 reverse split effective; split-adjusted trading expected to resume today on NYSE American
• Minnesota on track for initial revenue in Q1 2027 and full 40 megawatts IT load in Q2 2027
• Minnesota project-level debt financing progressing through confirmatory diligence
• Exit from legacy CleanCore cleaning business complete; Zone is now pure-play AI infrastructure
• Directors have invested $3,286,591 in Zone since August, including $786,591 by CEO
• Texas campus offers significant option value with no required capital exposure

HOUSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) — Zone Frontier Inc. (NYSE American: ZONE) (the “Company” or “Zone Frontier”) today provided a shareholder update on its Minnesota data center campus, its project-level debt financing process, the completion of its exit from the legacy CleanCore cleaning products business, insider share purchases and its Potter County, Texas data center campus. The update coincides with the effectiveness of the Company’s 1-for-60 reverse stock split and the resumption of trading of its common stock on a split-adjusted basis on the NYSE American today.

Reverse Stock Split and Resumption of Trading
The Company’s previously announced 1-for-60 reverse stock split became effective at 12:01 a.m. Eastern Time today, and the Company’s common stock is expected to resume trading on a split-adjusted basis on the NYSE American at market open today under the existing symbol “ZONE” and a new CUSIP number, 184492205. Every 60 shares of the Company’s common stock were automatically combined into one share, reducing the number of shares outstanding from approximately 509,892,887 to approximately 8,498,215. No fractional shares were issued in connection with the reverse stock split; any fractional share that otherwise would have resulted from the reverse stock split was rounded up to the nearest whole share.

Minnesota Campus: Execution on Track
The Company’s Minnesota data center campus remains on track to commence revenue with Cerebras Systems Inc. (NASDAQ: CBRS) in the first quarter of 2027 and to deliver its full 40 megawatts of critical IT load by the second quarter of 2027. The campus is supported by a 10-year Colocation Services Agreement with Cerebras, with two 10-year potential extension options.

Construction is progressing on schedule. Deposits have been placed on all major long-lead equipment with delivery timing on track. On site, vertical construction of the data hall and chiller building is advancing on completed footings and foundations, with structural steel rising and roof framing underway. Earthwork, underground utilities, and the power infrastructure to deliver the full 40 megawatts of critical load continue in parallel.

The Company’s project-level debt financing process for the Minnesota campus is progressing well and is in the confirmatory diligence phase. The financing is expected to be structured at the project special purpose vehicle level. Upon closing, the debt financing, together with the project’s equity capital, is expected to fully fund the project through full-scale operations.

“Minnesota is our top priority and has the full attention of our team,” said Tyler Hassen, Chief Executive Officer of Zone Frontier. “Construction is on track, we are advancing our debt financing toward closing, and we are focused every day on being a great partner to Cerebras.”

Transformation Complete
Earlier this month, the Company completed the sale of its legacy cleaning products business, including its wholly owned subsidiary CleanCore Global Limited, which, based on historical operating results, the Company estimates eliminated approximately $3 million in annual cash burn. With the sale, the Company has fully exited the CleanCore business and now operates as a pure-play AI infrastructure developer focused on power-enabled compute campuses, with lean operations and disciplined corporate spending. Additional information regarding the sale, including the consideration payable to the Company in the form of a promissory note and a potential earnout, is included in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2026.

Insider Share Purchases
Members of the Company’s Board of Directors have invested a total of $3,286,591 in the Company since August, including $786,591 from the Chief Executive Officer Tyler Hassen. In the Company’s approximately $100 million public offering completed in August 2026, Mr. Hassen purchased 2,000,000 shares of common stock and accompanying warrants, and another member of the Board of Directors purchased 10,000,000 shares of common stock and accompanying warrants. In addition, during October 2026, Mr. Hassen purchased 2,500,000 shares of common stock in open market transactions. In total, directors have purchased approximately 241,667 shares of common stock on a post-reverse-split basis (14,500,000 shares on a pre-split basis) since August, including approximately 75,000 post-split shares (4,500,000 pre-split shares) purchased by Mr. Hassen. These purchases have been reported on Forms 4 filed with the Securities and Exchange Commission.

“Our board and I have invested in Zone because we believe in what we are building,” said Mr. Hassen. “Our interests are fully aligned with our shareholders, and we are confident in our strategy and in the long-term value we are working to create.”

Texas Campus: Option Value with Significant Potential
At its Potter County, Texas data center campus, being developed in partnership with HST Technologies, Inc. and its technology platform, the Company continues to make progress with potential tenants and key vendors while permitting and power interconnection studies are completed. The campus is expected to be initially built in phases of 50 to 100 megawatts up to 200 megawatts, with ample potential to exceed well over 500 megawatts over time.

The Company’s capital investment in Texas is entirely within its control. The Company has no obligation to build, and base rent under its long-term ground lease begins only when construction starts on each site area. Under the joint venture agreement with HST, the Company’s initial $100 million capital contribution is scheduled for April 2, 2027. If it is not fully invested by then, HST has no recourse against the Company; the only potential consequence is minimal dilution of the Company’s interest in the project.

The Company intends to invest in Texas only as long-term tenant lease agreements are signed and power capacity and permits are secured, and views the campus as significant option value for shareholders. The approximately 4,077-acre site is located in the Southwest Power Pool (SPP) region and benefits from onsite water and nearby substations, fiber, natural gas pipelines and wind capacity.

“We are very optimistic about our Texas campus,” said Mr. Hassen. “We continue to expect to be in a position to raise project-level equity and debt capital on attractive terms by the end of the first quarter of 2027, and we have a great relationship with our partners at HST. We will act in the best interest of our shareholders, in close coordination with HST, as we move this project forward.”

“Our partnership with Zone brings together a premier site de-risked by our technology stack, and a team that is focused on execution,” said Rudy Roy, Chief Executive Officer of HST Technologies, Inc. “We are making real progress with tenants and vendors, and we are excited about how our software platform will help scale critical AI Infrastructure in the Texas Panhandle.”

“Minnesota is just the beginning,” added Mr. Hassen. “With our transformation complete, our flagship campus on track and a Texas campus that gives us meaningful optionality, we believe Zone is well positioned to build a leading AI infrastructure business.”

For more information, visit www.zonefrontier.com.

About Zone Frontier Inc.
Zone Frontier Inc. (NYSE AMERICAN: ZONE) is helping to build the critical infrastructure that powers the AI economy. Through a growing pipeline of projects, the Company aims to help meet the increasing demand for compute capacity, power, and digital infrastructure required by the world’s leading AI companies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the timing of capacity delivery at the Company’s Minnesota data center campus, the timing of construction and equipment delivery at the Minnesota campus, the expected commencement of revenue and the expected contract value under the Company’s colocation agreement with Cerebras, the expected closing, terms and sufficiency of project-level debt financing for the Minnesota campus, the resumption of trading of the Company’s common stock on a split-adjusted basis, the development of the Company’s Texas data center campus and the amount, timing and financing of any capital deployment there, including the timing and terms of any project-level equity and debt financing for the Texas campus, the estimated cost savings from the sale of the Company’s legacy business, the Company’s business strategy and pipeline of projects, and the Company’s operation as an AI infrastructure business. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “could,” “should,” “estimates,” “projects,” “potential,” “focused on,” “aims,” “expand,” “expected,” “look forward,” and similar expressions. These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the risk that project-level debt financing for the Minnesota campus does not close on the anticipated terms or timeline or at all; construction, equipment, permitting, power or interconnection delays that could affect delivery timelines under the Company’s colocation agreement; the Company’s dependence on a single customer for its Minnesota campus and the risk that revenue under the colocation agreement commences later than expected or is less than expected; the collection of amounts payable to the Company under the promissory note and potential earnout from the sale of its legacy business; the risk that the cost savings from the sale of the legacy business are less than estimated; the Company’s ability to secure tenants, power, interconnection, permits and project-level financing for its Texas data center campus; the risk that, if the Company does not fund its capital contributions to the Texas joint venture when scheduled, its percentage interest in the joint venture could be diluted; the effects of the reverse stock split, including on the market price and liquidity of the Company’s common stock and on the exercise price of the Company’s outstanding warrants; the Company’s ability to maintain the listing of its common stock on the NYSE American; the highly speculative and uncertain nature of the Company’s AI critical infrastructure business; the Company’s ability to operate successfully as a pure-play AI infrastructure company following the sale of its legacy business; the Company’s limited operating history and experience in the data center and AI infrastructure industries; the status of the Company’s operations, results of operations, growth strategy and liquidity; and general economic, financial, capital market and industry conditions.

For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements are qualified in their entirety by this cautionary statement.

MEDIA CONTACT
Angela Gorman | AMWPR
angela@amwpr.com | 917.348.0083

SOURCE Zone Frontier Inc. (NYSE AMERICAN: ZONE)

Combining entertainment collectibles with preservation and authentication technology, Alliance Authentic continues to connect with collectors through exclusive releases and fan experiences

PLANTATION, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (Nasdaq: AENT), a scaled entertainment commerce and collectibles platform serving content owners, brands, retailers and fans across music, movies, gaming, licensed merchandise and collectibles, with proprietary brands, authentication technology and reach across more than 35,000 retail and e-commerce storefronts, today announced that its Alliance Authentic division will showcase an exclusive collection of Danny Elfman signed collectibles, alongside preserved vinyl records and collectible figures, at L.A. Comic Con, taking place October 30 through November 1 at the Los Angeles Convention Center.

At Alliance Authentic’s booth (#1354), collectors will find something they cannot get anywhere else: five Danny Elfman signed pieces exclusively for Alliance Authentic, including The Simpsons Main Title Theme on 10-inch vinyl, The Nightmare Before Christmas, Beetlejuice and Justice League on LP, plus a Jack Skellington figure from Handmade By Robots. Each piece is limited to just five, and every signature is authenticated. The signed pieces are available only at L.A. Comic Con, with any remaining pieces offered to collectors registered with Alliance Authentic after the show.

The brand made its Comic Con debut in San Diego this summer, where Nerd News Social called it “the collecting platform for a new generation,” and appeared at New York Comic Con earlier this month, where Temple of Geek said Alliance Authentic “takes vinyl collecting to a new level.”

The booth will also carry more than 65 preserved vinyl soundtracks across film, TV, anime and games, from Spirited Away and KPop Demon Hunters to Scream, Ghostbusters, Star Wars, Harry Potter, The Lord of the Rings and more, plus preserved Funko Pop! and Handmade By Robots figures. Fans can step inside a nine-foot Alliance Authentic collectible box for a photo, and collectors with a registered Alliance Authentic account who take one get a free Handmade By Robots Scooby-Doo micro figure, while supplies last. Everything at the booth, including the signed Elfman pieces, is available first come, first served.

Alliance Authentic preserves the pieces fans care about most. Every piece at the booth, the signed Elfman pieces included, is curated, numbered, limited and sealed in Certified Uncirculated condition, so none ever reached a retail shelf. An NFC chip gives each piece a verified identity. Collectors tap the chip to confirm it, claim it, and keep its full history with it if it ever changes hands.

“We’re so excited to bring the full Alliance Authentic experience to the fan community at L.A. Comic Con,” said Jeffrey Smith, SVP of Marketing at Alliance Authentic. “Danny Elfman signatures on some of the most important work of his career, the week of Halloween? That’s incredibly special. If you love horror, sci-fi or anime, we preserved some of the coolest pieces out there for you. I can’t wait to see everyone at the booth.”

About Alliance Authentic

Alliance Authentic preserves the records, figures, and films fans care about most. Every preserved piece meets five standards: Curated, Numbered, Limited, Certified Uncirculated and NFC-Secured. Each carries a verified identity and provenance that travels with it to every future collector. Alliance Authentic is home to The Ultimate Vinyl Collectible™ and works with partners including Handmade By Robots and Funko. Alliance Authentic is a division of Alliance Entertainment (Nasdaq: AENT). Learn more at allianceauthentic.com.

About Alliance Entertainment

Alliance Entertainment (NASDAQ: AENT) is a premier distributor and fulfillment partner for the entertainment and pop culture collectibles industry. With more than 340,000 unique in-stock SKUs – including over 57,300 exclusive titles across compact discs, vinyl LPs, DVDs, Blu-rays, and video games – Alliance offers the largest selection of physical media in the market. Our vast catalog also includes licensed merchandise, toys, retro gaming products, and collectibles, serving over 35,000 retail locations and powering e-commerce fulfillment for leading retailers. Alliance also owns and operates proprietary collectibles brands, including Handmade by Robots™, a stylized vinyl figure line featuring licensed characters from leading entertainment franchises, and Alliance Authentic™, a premium platform for authentic, certified, and individually numbered entertainment collectibles. In addition, Alliance operates Endstate Authentic, a dedicated NFC-enabled authentication and digital product identity platform supporting authenticated collectibles, resale, and brand protection. Leveraging decades of operational expertise, exclusive sourcing relationships, and a capital-light, scalable infrastructure, Alliance connects fans and collectors to the products, franchises, and experiences they value across formats and generations. For more information, visit www.aent.com.

Forward Looking Statements

Certain statements included in this Press Release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether identified in this Press Release, and on the current expectations of Alliance’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Alliance. These forward-looking statements are subject to a number of risks and uncertainties, including risks relating to the anticipated growth rates and market opportunities; changes in applicable laws or regulations; the ability of Alliance to execute its business model, including market acceptance of its systems and related services; Alliance’s reliance on a concentration of suppliers for its products and services; increases in Alliance’s costs, disruption of supply, or shortage of products and materials; Alliance’s dependence on a concentration of customers, and failure to add new customers or expand sales to Alliance’s existing customers; increased Alliance inventory and risk of obsolescence; Alliance’s significant amount of indebtedness; our ability to refinance our existing indebtedness; risks that a breach of the revolving credit facility could result in the lender declaring a default and that the full outstanding amount under the revolving credit facility could be immediately due in full, which would have severe adverse consequences for the Company; known or future litigation and regulatory enforcement risks, including the diversion of time and attention and the additional costs and demands on Alliance’s resources; Alliance’s business being adversely affected by increased inflation, uncertainty regarding tariffs, higher interest rates and other adverse economic, business, and/or competitive factors; geopolitical risk and changes in applicable laws or regulations; as well as our financial condition and results of operations; substantial regulations, which are evolving, and unfavorable changes or failure by Alliance to comply with these regulations; product liability claims, which could harm Alliance’s financial condition and liquidity if Alliance is not able to successfully defend or insure against such claims; availability of additional capital to support business growth; and the inability of Alliance to develop and maintain effective internal controls.

For media inquiries, please contact:

Max Lefkowitz – mlefkowitz@shorefire.com
Anna DeNelsky – adenelsky@shorefire.com
Matt Hanks – mhanks@shorefire.com

For investor inquiries, please contact:

Dave Gentry
RedChip Companies, Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
AENT@redchip.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/14c94710-088a-4307-b357-c25e6f2f64b8

MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that key analytical development activities are underway, including immunogenicity assay feasibility, pharmacokinetic method optimization and stability testing, supporting preparations for the planned Phase 1b, First-In-Human study of the Company’s lead clinical candidate, PPC-001, in up to 50 advanced cancer patients with solid tumors.

“Propanc continues to advance its analytical development activities in parallel with preparations for its Phase 1b First-In-Human study,” said Dr. Ralf Brandt, Propanc’s Research & Development Director. “The ongoing feasibility assessment of immunogenicity assays, together with the planned optimization of pharmacokinetic bioanalytical methods and stability testing, represents an important component of the Company’s clinical development strategy.”

Key achievements include:

• Encouraging stability results for PPC-001 in human blood matrices: Bioanalytical studies demonstrated that the two proenzyme components of PPC-001, trypsinogen and chymotrypsinogen, remained detectable without evidence of significant degradation over the investigated sample-handling periods.
• Stability demonstrated across three human donors: Follow-up experiments conducted by FyoniBio evaluated serum and plasma samples from three individual donors, strengthening the initial feasibility findings.
• Stability over 60 minutes at room temperature: The September study demonstrated recovery results generally exceeding 85% after 60 minutes, supporting the feasibility of clinical blood sample collection and processing procedures.
• Successful application of mass spectrometry: LC-MS-based analytical methods were used to measure both proenzyme components in human serum and plasma, providing a foundation for further development of pharmacokinetic assays.
• Progress in immunogenicity assay development: Laboratory experiments demonstrated successful preparation of biotin- and sulfoTAG-labelled trypsinogen and chymotrypsinogen reagents, with no degradation observed by SDS-PAGE under the tested labelling conditions.
• Additional evidence of short-term reagent stability: Labelled assay reagents showed no detectable degradation by SDS-PAGE following storage for one day at 4°C under the tested conditions, supporting continued development of anti-drug antibody (ADA) assays.

Advancement toward clinical bioanalytical readiness – together, these findings support continued assay optimization and pre-validation activities required for the planned clinical development of PPC-001 and are structured in the three key areas based on the unique properties of treatment. These activities are expected to provide the analytical foundation required to support the evaluation of PPC-001 during its clinical development program.

1. Anti-Drug Antibody Assay Development: The feasibility assessment for the development of two ADA assays, targeting the individual proenzyme components trypsinogen and chymotrypsinogen, is currently underway. The feasibility program is evaluating the suitability of existing positive control antibodies to support the development of reliable immunogenicity assays. Following successful feasibility assessment, the program is scheduled to progress to assay establishment and subsequent validation.
2. Pharmacokinetic Bioanalytical Method Development: The Company has established a structured analytical development program aimed at optimizing the sensitivity and performance of bioanalytical methods for measuring PPC-001 components in clinical samples. The program includes the evaluation of stable isotope-labelled peptides as internal standards, strategies to minimize biological matrix effects, and optimization of sample volumes to improve analytical sensitivity. Additional activities will focus on reducing sample analysis time and establishing a suitable analytical method for subsequent clinical application.
3. Stability Assessment and Analytical Support: Stability testing activities covering the drug product and its analytical characteristics are included in the development program. The analytical program is intended to generate the data necessary to support appropriate sample handling, analytical reliability and clinical bioanalytical assessments.

“The work undertaken led by Dr Ralf Brandt, our R&D Director, his team, and our partner CRO is of a high standard and provides an excellent framework for our world-first study for PPC-001 in advanced cancer patients,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “PPC-001, a combination therapy consisting of two pancreatic proenzymes from naturally derived sources is a unique approach to cancer treatment which has the capacity to reverse the effects of cancer cell dissemination and recurrence. By undertaking these important bioanalytical activities, we are going to obtain great insight into the effects of PPC-001.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com